Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000950170-25-021289
Filing Date
2025-02-14
Accepted
2025-02-14 16:30:03
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 10361
  Complete submission text file 0000950170-25-021289.txt   12318
Mailing Address 5 RADNOR CORPORATE CENTER SUITE 500 100 MATSONFORD RD RADNOR PA 19087
Business Address 5 RADNOR CORPORATE CENTER SUITE 500 100 MATSONFORD RD RADNOR PA 19087 484-801-4670
MARINUS PHARMACEUTICALS, INC. (Subject) CIK: 0001267813 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-88269 | Film No.: 25629591
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O MAPLES CORPORATE SERVICES LIMITED BOX 309, UGLAND HOUSE GRAND CAYMAN E9 KY1-1104
Business Address C/O MAPLES CORPORATE SERVICES LIMITED BOX 309, UGLAND HOUSE GRAND CAYMAN E9 KY1-1104 86 21 60252100
Panacea Innovation Ltd (Filed by) CIK: 0002010692 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A